A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C

Clinical Trial

. 2001 Aug;34(2):395-403.

doi: 10.1053/jhep.2001.26371.

Affiliations

PMID: 11481625
DOI: 10.1053/jhep.2001.26371

Clinical Trial

K L Lindsay et al. Hepatology. 2001 Aug.

Abstract

This international, randomized, active-controlled, parallel-group, double-blind dose-finding study compared peginterferon alfa-2b (PegIntron) to interferon alfa-2b for the initial treatment of compensated chronic hepatitis C. We randomly assigned 1,219 subjects to receive either the standard three-times-weekly (TIW) interferon alfa-2b dose (3 MIU) or the once-weekly (QW) peginterferon alfa-2b (0.5, 1.0, or 1.5 microg/kg). Subjects were treated for 48 weeks and then followed for an additional 24 weeks. All 3 peginterferon alfa-2b doses significantly (P < or =.042) improved virologic response rates (loss of detectable serum HCV RNA) after treatment and after follow-up, as compared with interferon alfa-2b. Unlike the end-of-treatment virologic response, the sustained virologic response rate was not dose-related above 1.0 microg/kg peginterferon alfa-2b because of a higher relapse rate among patients treated with 1.5 microg/kg peginterferon alfa-2b, particularly among patients infected with genotype 1. All 3 peginterferon alfa-2b doses decreased liver inflammation to a greater extent than did interferon alfa-2b, particularly in subjects with sustained responses. No new adverse events were reported, and the majority of adverse events and changes in laboratory values were mild or moderate. In conclusion, peginterferon alfa-2b maintained (0.5 microg/kg) or surpassed (1.0, 1.5 microg/kg) the clinical efficacy of interferon alfa-2b while preserving its safety profile. The higher rate of virologic response during treatment with 1.5 microg/kg peginterferon alfa-2b in patients infected with genotype 1 and high viral levels warrants further evaluation.

PubMed Disclaimer

Cited by

Reducing Peg-IFN doses causes later virologic response or no response in HCV genotype 1 patients treated with Peg-IFN alfa-2b plus ribavirin.
Oze T, Hiramatsu N, Song C, Yakushijin T, Iio S, Doi Y, Oshita M, Hagiwara H, Mita E, Ito T, Inui Y, Hijioka T, Tamura S, Yoshihara H, Inoue A, Imai Y, Hayashi E, Kato M, Miyazaki M, Hosui A, Miyagi T, Yoshida Y, Tatsumi T, Kiso S, Kanto T, Kasahara A, Hayashi N, Takehara T. Oze T, et al. J Gastroenterol. 2012 Mar;47(3):334-42. doi: 10.1007/s00535-011-0498-3. Epub 2011 Nov 23. J Gastroenterol. 2012. PMID: 22109353
Pharmacokinetics of the antiviral agent beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine in rhesus monkeys.
Asif G, Hurwitz SJ, Shi J, Hernandez-Santiago BI, Schinazi RF. Asif G, et al. Antimicrob Agents Chemother. 2007 Aug;51(8):2877-82. doi: 10.1128/AAC.00193-07. Epub 2007 Jun 11. Antimicrob Agents Chemother. 2007. PMID: 17562805 Free PMC article.
Optimal clinical trial designs for immune-based therapies in persistent viral infections.
Smith KA. Smith KA. Med Immunol. 2002 Nov 21;1(1):4. doi: 10.1186/1476-9433-1-4. Med Immunol. 2002. PMID: 12459051 Free PMC article.
Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C.
Koretz RL, Pleguezuelo M, Arvaniti V, Barrera Baena P, Ciria R, Gurusamy KS, Davidson BR, Burroughs AK. Koretz RL, et al. Cochrane Database Syst Rev. 2013 Jan 31;2013(1):CD003617. doi: 10.1002/14651858.CD003617.pub2. Cochrane Database Syst Rev. 2013. PMID: 23440791 Free PMC article. Review.
25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end.
Heim MH. Heim MH. Nat Rev Immunol. 2013 Jul;13(7):535-42. doi: 10.1038/nri3463. Epub 2013 Jun 7. Nat Rev Immunol. 2013. PMID: 23743475 Review.

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C - PubMed (original) (raw)